Wiseguyreports.Com Adds “Hemophilia Management -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database
The Global Hemophilia Management Market was worth $5182 million in 2015 and estimated to be growing at a CAGR of 1.62%, to reach $5616 million by 2020. Hemophilia is a genetic disorder which impairs body`s ability to control blood clotting. Hemophilia usually occurs in males it is estimated that about 1 in 5000 males that are born each year contain hemophilia.
Hemophilia is categorized into three levels depending on its severity as severe, moderate and mild. About 80% of the hemophilia patients are considered to suffer from severe type. The worldwide incidence of hemophilia is estimated at more than 400,000 people. It is estimated that about 75% of the hemophilia patients do not receive adequate treatment. Growing prevalence of the disease and increasing usage of recombinant product is expected to drive the market growth.
Technological advancements and advancements in the novel coagulating factors and are also fuelling the growth of global Hemophilia Management market. Rising investments in Research and developments for hemophilia products is also driving the market growth. However lack of available medication, awareness of this disease and high cost of treatment are the major restraining factors in the market. Advancements in gene therapy and increasing number of drug approvals for treatment of hemophilia provide immense growth opportunities in the market.
Global Hemophilia management market is segmented on the basis of type of hemophilia and type of drug. By type of hemophilia it is further sub segmented into Hemophilia A and Hemophilia B.
Based on type of drug it is further sub segmented into Octocogalfa, Nonacogalfa, Desmopressin and other drugs.
Request for Sample Report @ https://www.wiseguyreports.com/sample-request/635488-hemophilia-management-market-by-forecasts-2015-2020
Hemophilia A is projected to have the highest growth rate driven by large number of patients suffering from hemophilia A On the basis of geography Global hemophilia management market is analyzed under various regions namely North America, Europe, Asia-pacific, Latin America and Africa & Middle-East. North America is the largest market for hemophilia management accounting for approximately XX% due to high government support and the increasing number of patients suffering from hemophilia. Europe is the second largest market for hemophilia management.
Asia-Pacific region is estimated to be the fastest growing region owing to its high population base and increasing healthcare expenditure. Latin America region provide lucrative opportunity for growth attributed to local government support and increasing focus of global players towards emerging economies.
Some of the major companies discussed in the report are
Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB
Table of Content
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 BY Type
5.1.1 Hemophilia A
5.1.2 Hemophilia B
5.2 By Drug
5.2.4 Other drugs
6. Geographical Analysis
6.1 North America
6.1.2 United States
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)